EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis

Mafalda Bacalhau, Mariana Camargo iD, Grace A V Magalhães-Ghiotto iD, Sybelle Drumond, Carlos Henrique M Castelletti iD, Miquéias Lopes-Pacheco iD

Pharmaceuticals · 08.03.2023 · 16 (3) · 410

DOI: 10.3390/ph16030410 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 08.03.2023. Verfasst von Mafalda Bacalhau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences (United States), Cystic Fibrosis Foundation, Gilead Sciences USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a potentially fatal monogenic disease that causes a progressive multisystemic pathology. Over the last decade, the introduction of CF transmembrane conductance regulator (CFTR) modulator drugs into clinical practice has profoundly modified the lives of many people with CF (PwCF) by targeting the fundamental cause of the disease. These drugs consist of the potentiator ivacaftor (VX-770) and the correctors lumacaftor (VX-809), tezacaftor (VX-661), and elexacaftor (VX-445). In particular, the triple combination of CFTR modulators composed of elexacaftor, tezacaftor, and ivacaftor (ETI) represents a life-changing therapy for the majority of PwCF worldwide. A growing number of clinical studies have demonstrated the safety and efficacy of ETI therapy in both short- and long-term (up to two years of follow-up to date) and its ability to significantly reduce pulmonary and gastrointestinal manifestations, sweat chloride concentration, exocrine pancreatic dysfunction, and infertility/subfertility, among other disease signs and symptoms. Nevertheless, ETI therapy-related adverse effects have also been reported, and close monitoring by a multidisciplinary healthcare team remains vital. This review aims to address and discuss the major therapeutic benefits and adverse effects reported by the clinical use of ETI therapy for PwCF.

Schlagwörter

Stichwörter der Autor:innen

KaftrioTrikaftaadverse effectscase reportclinical efficacyclinical trialobservational studyprecision medicinereal-life studysafety

Autor:innen und Institutionen

  • Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal.
  • Department of Surgery, Division of Urology, Sao Paulo Federal University, Sao Paulo 04039-060, SP, Brazil.
  • Department of Biotechnology, Genetics, and Cell Biology, Biological Sciences Center, State University of Maringa, Maringa 87020-900, PR, Brazil.
  • Center for Research in Bioethics and Social Health, School of Magistracy of the State of Rio de Janeiro, Rio de Janeiro 20010-090, RJ, Brazil.
  • Molecular Prospecting and Bioinformatics Group, Keizo Asami Institute, Federal University of Pernambuco, Recife 50670-901, PE, Brazil.

ORCID-Profile: Mariana Camargo, Grace A V Magalhães-Ghiotto, Carlos Henrique M Castelletti, Miquéias Lopes-Pacheco

Förderung

  • Gilead Sciences (United States)
  • Cystic Fibrosis Foundation
  • Gilead Sciences USA
  • Cystic Fibrosis Foundation USA

Zitieren

APA

Bacalhau, M., Camargo, M., Magalhães-Ghiotto, G. A. V., Drumond, S., Castelletti, C. H. M., & Lopes-Pacheco, M. (2023). Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 16(3), 410. https://doi.org/10.3390/ph16030410

Vancouver

Bacalhau M, Camargo M, Magalhães-Ghiotto GAV, Drumond S, Castelletti CHM, Lopes-Pacheco M. Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals. 2023;16(3):410. doi:10.3390/ph16030410

BibTeX
@article{Bacalhau2023,
  author = {Bacalhau, Mafalda and Camargo, Mariana and Magalhães-Ghiotto, Grace A V and Drumond, Sybelle and Castelletti, Carlos Henrique M and Lopes-Pacheco, Miquéias},
  title = {Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {3},
  pages = {410},
  doi = {10.3390/ph16030410}
}
Kostenlos starten →